Can a simple vaccine boost CAR T-Cell success in lymphoma?
NCT ID NCT04745559
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy can improve the immune system's ability to fight pneumococcus bacteria in people with certain types of lymphoma. About 26 participants with relapsed or hard-to-treat B-cell lymphomas will receive the vaccine at specific times around their CAR T-cell treatment. The main goal is to see if this approach increases protective antibody levels 90 days after therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.